The biggest crowdfunding platforms are not always the most successful by every measure. This week’s Chart of the Week looks at Reg CF and Reg A+ offerings that closed between January 2025 and June 2026 to see which platforms generated the strongest investor demand. The data suggests two winning models: scale and specialization. Platforms like StartEngine and DealMaker benefit from large investor networks, while smaller platforms can perform well by focusing on categories investors understand deeply, from industrial moonshots and real estate to hotels, energy, film, and local businesses.

The takeaway: platform choice matters because it shapes the investor audience a company is speaking to.

Join Kingscrowd founder & CEO Chris Lustrino and the Kingscrowd investment team for a live Demo Day featuring promising startups currently raising capital online. Hear directly from founders, learn about their businesses, and gain insights from the team that analyzes hundreds of private investment opportunities every year.

Can baby formula get closer to human breast milk?

This week on the Kingscrowd Podcast, Brian Belley and Léa Bouhelier-Gautreau discuss proposed SEC reforms that could improve transparency for startup investors before diving into Harmony Baby Nutrition, a company developing next-generation infant formula using human milk proteins. Learn why Kingscrowd Capital invested and what investors should consider before backing biotech-style opportunities in consumer markets.

Listen in your browser

By Teddy Lyons \ Deal Report

Brief: Synergy Global Foods is a B2B foodservice manufacturer of medically tailored meals, the dietitian-designed meals built for people managing serious chronic conditions like heart disease, diabetes, kidney disease, and cancer. The company runs four production facilities with capacity for up to 500,000 meals a week, sells into healthcare and institutional channels rather than direct to to consumers, and is raising on StartEngine via a SAFE at a $15M valuation cap with a 20% discount.

Teddy’s Quick Take: 

Last June, Kingscrowd Capital invested in Vegetable + Butcher, and when I wrote it up I led with a confession: I rarely invest in food companies. Margins are thin, the space is crowded, and maybe one in a hundred clears the bar I need to see before writing a check. V+B cleared it on the strength of 45% gross margins, a 10:1 LTV to CAC ratio, and a roughly $10M revenue run rate off just 2,500 loyal subscribers.

Synergy Global Foods is also a "food is medicine" company, which is what first caught my eye, but it sits at almost the opposite end of that thesis from V+B. Synergy is a manufacturer of medically tailored meals, the clinically formulated meals built for people managing heart disease, diabetes, kidney disease, or cancer, and it can produce up to half a million of them a week across four facilities. The market need is real and well documented: a landmark Massachusetts Medicaid study this month found these meals led to fewer hospitalizations and lower costs, and 13 states now run Medicaid waivers that reimburse for them.

The bigger difference from V+B is who actually pays. V+B's customer is the person eating the meal, swiping a card for a subscription, which is why its revenue is recurring and sticky. Synergy's real customer is almost never the patient. It is a health plan, a Medicaid managed care org, or a senior living operator that contracts for the meals, so revenue is won through contracts and RFPs rather than card swipes. That makes the top line lumpy, where a single account win or loss can swing it hard, and it leans on reimbursement policy that changes state by state.

That is where my skepticism kicks in, though credit is due first. Synergy still does real volume at roughly $9.9M in revenue last year, and it turned a $2.3M net profit in 2024, which tells me they actually know how to run a profitable operation rather than burn capital chasing growth. What gives me pause is the trajectory. That $9.9M was down about 35% from $15.4M the year before, the 2024 profit swung to a roughly breakeven loss in 2025, and gross margins sit around 29% against V+B's 45%, with about $6.2M of short-term debt and very little cash. For a company with this much wind at its back, a one-third revenue drop is the first thing I would want explained, and the raise materials do not. My instinct is that it is contract-driven, the kind of swing you get when a big account or reimbursement program rolls off, but that is exactly the thing I would not want to guess at.

So I land cautious. The category is one I believe in, the capacity is real, and the business has proven it can be profitable. But revenue moving the wrong way, thin margins, and the contract concentration that likely caused the drop are too important to wave past, especially on a SAFE where you are betting on the next round to set the price. If I took this further, I would want to know what drove the 35% decline, how concentrated the customer base is, and what the contracted pipeline looks like into 2027 as more states fund these meals. Good answers there and it gets a lot more interesting. Until then, it is one I am watching rather than backing.

Eliaz Therapeutics

By Léa Bouhelier-Gautreau

Sepsis kills more people every year than all cancers combined, yet there is still no FDA-approved treatment that directly targets the disease process. Eliaz Therapeutics believes XGal-3 could change that, and investors and the company is raising again to bring the device into human trials.

Musaffa

By Léa Bouhelier-Gautreau

It's not because investors keep investing that a company should keep increasing its valuation. Musaffa's valuation grew from $29.4 million in 2024 to now $126.2 million, while 2025 revenues only reached $280,000. I think that the business can grow, but at this price, I'm wondering where the upside for investors is.

That's a wrap on this week's issue!

Thanks for reading — your time and attention are what make the Kingscrowd newsletter worth building. If you found something useful this week, forward it to a fellow investor.